Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

V Joly; M Moroni; E Concia; A Lazzarin; B Hirschel; J Jost; F Chiodo; Z Bentwich; W C Love; D A Hawkins; E G Wilkins; A J Gatell; N Vetter; C Greenwald; W W Freimuth; W de Cian

doi:10.1128/AAC.44.11.3155-3157.2000

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Antimicrob Agents Chemother. 2000 Nov;44(11):3155-7. doi: 10.1128/AAC.44.11.3155-3157.2000.

Authors

V Joly¹, M Moroni, E Concia, A Lazzarin, B Hirschel, J Jost, F Chiodo, Z Bentwich, W C Love, D A Hawkins, E G Wilkins, A J Gatell, N Vetter, C Greenwald, W W Freimuth, W de Cian

Affiliation

¹ Department of Internal Medicine, Hôpital Bichat, Paris, France. [email protected]

Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Publication types

Clinical Trial
Clinical Trial, Phase III
Randomized Controlled Trial

MeSH terms

Anti-HIV Agents / therapeutic use*
Delavirdine / therapeutic use*
Double-Blind Method
Drug Resistance, Microbial
Drug Therapy, Combination
HIV Infections / drug therapy*
HIV Reverse Transcriptase / genetics
HIV-1 / drug effects
HIV-1 / genetics
Humans
Treatment Outcome
Zidovudine / therapeutic use

Substances

Anti-HIV Agents
Zidovudine
Delavirdine
HIV Reverse Transcriptase